← Oncology Approval Tracker

FDA DECISION ·

Pemfexy + pembrolizumab and platinum

pemetrexed plus pembrolizumab and platinum chemotherapy · Eagle Pharmaceuticals

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Initial combination treatment for metastatic nonsquamous NSCLC without EGFR or ALK genomic aberrations, using Pemfexy with pembrolizumab and platinum chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The action adds a specific first-line combination to the Pemfexy label.

What research teams should watch

Verify EGFR and ALK results and check the exact pemetrexed product in treatment orders.

PRIMARY RECORDS

Sources